Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sucralfate: worldwide experience in recurrence therapy.

I N Marks

    Journal of Clinical Gastroenterology
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The treatment of peptic ulcer disease.

    Current opinion in gastroenterology·2006
    Same author

    The medical treatment of peptic ulcer disease.

    Current opinion in gastroenterology·2006
    Same author

    The treatment of peptic ulcer disease.

    Current opinion in gastroenterology·2006
    Same author

    The pepsinogen releasing effect of Helicobacter pylori lipopolysaccharide.

    Helicobacter·2002
    Same author

    Helicobacter pylori in Africa: observations on an 'enigma within an enigma'.

    Journal of gastroenterology and hepatology·1999
    Same author

    Helicobacter pylori: therapeutic targets.

    The Yale journal of biology and medicine·1999

    Sucralfate is a safe and effective treatment for peptic ulcers. A twice-daily dosage may be more convenient for short-term healing, with a nightly dose for long-term management.

    Area of Science:

    • Gastroenterology
    • Pharmacology

    Background:

    • Peptic ulcer disease affects millions globally.
    • Sucralfate is a cytoprotective agent used for ulcer treatment.

    Purpose of the Study:

    • To evaluate the efficacy and optimal dosage of sucralfate for peptic ulcer treatment.
    • To assess the impact of smoking and formulation on sucralfate's effectiveness.

    Main Methods:

    • Review of international studies on sucralfate efficacy.
    • Comparison of different sucralfate dosage regimens (b.i.d. vs. q.i.d.).
    • Analysis of sucralfate's effect on healing in smokers and comparison of tablet vs. granule formulations.

    Main Results:

    • Sucralfate demonstrates safety and efficacy in both short- and long-term peptic ulcer treatment.

    Related Experiment Videos

  • A 2 g twice-daily (b.i.d.) dosage may offer superior short-term duodenal ulcer healing compared to 1 g four times daily (q.i.d.).
  • A 2 g nightly maintenance dose is suitable for long-term management; smoking does not impede healing, and granules show no advantage over tablets.

    • Conclusions:

    • Sucralfate is a reliable therapeutic option for peptic ulcers.
    • Optimized dosing schedules can enhance patient convenience and treatment outcomes.
    • Treatment effectiveness is not compromised by smoking or formulation type.